Abstract
Introduction

60
Heart failure (HF) is a major cause of death among the elderly in many countries and 61 has become a significant public health problem (3). Heart failure with preserved 62 ejection fraction (HFpEF), which constitutes approximately half of all HF patients, has contribute to the pathogenesis of HFpEF (15, 17, 35) , which substantially differs from 67 that of HFrEF (4, 26) . Several biomarkers have been identified to estimate the prognosis 68 and select the appropriate therapy for chronic HF patients (34). Serum uric acid (UA), 69 produced in the terminal step of purine nucleotide metabolism by xanthine oxidase 70 (XO), is a predictor of mortality in HFrEF, independent of chronic kidney disease (11, 71 30). However, the impact of serum UA on mortality in patients with HFpEF remains 72 unclear.
73
Therefore, the aims of the present study were to investigate clinical features, cardiac 74 function, arterial stiffness, exercise capacity, and cardiac and all-cause mortalities in
Methods
78
Subjects and study protocol 79 This was a prospective observational study that enrolled consecutive symptomatic 80 HFpEF patients that were hospitalized for treatment of decompensated HF and 
Results
186
The clinical features of the present study's subjects are summarized in and sodium did not differ between the two groups. Parameters of echocardiography,
196
CAVI and cardio-pulmonary exercise tests are summarized in Table 3 . CAVI was 197 significantly higher in the hyperuricemia group than in the non-hyperuricemia group.
198
Although left and right ventricular systolic function by echocardiography did not differ 199 between the two groups, peak VO 2 , end-tidal CO 2 at respiratory compensation point,
200
and anaerobic threshold were significantly lower, and the VE/VCO 2 slope was higher in 201 the hyperuricemia group than in the the non-hyperuricemia group. Moreover, there was a weak positive correlation between serum UA and CAVI (R = 0.167, P = 0.029), and 203 no correlation between peak VO 2 , VE/VCO 2 slope, and serum UA, respectively. higher in the hyperuricemia group than in the non-hyperuricemia group (P <0.001).
210
There was no significant difference in cardiac and all-cause mortalities between 211 antihyperuricemic therapy group (n=92) or non-antihyperuricemic therapy group 212 (n=162) in HFpEF patients with hyperurecemia (P = 0.477 and P = 0.695, respectively).
213
The Cox proportional hazard model was used to examine the prognostic value 214 of hyperuricemia in HFpEF patients (Tables 4-5 
Conclusions and perspectives
301
Hyperuricemia was an independent predictor of all-cause mortality in HFpEF patients.
302
Our study showed that the presence of hyperuricemia indicates progressed arterial Figure 2 
